Zytiga

Generic Name: abiraterone

Drug Class: Hormone Therapy Medications

Company: Janssen

Approval Status: Approved

Generic Version Available: No

Drug Indication

Zytiga is a CYP17 inhibitor approved for metastatic prostate cancer that progresses despite low testosterone levels (known as castration-resistant) and for high-risk castration-sensitive prostate cancer.

General Info



Testosterone and other male hormones (androgens) stimulate prostate cancer growth. Medical or surgical castration reduces testosterone levels, but other cells

in the body can still make androgens. Zytiga blocks an enzyme called CYP17 needed for androgen production. It should be used with GnRH agonists to stop testosterone production.

Studies showed that Zytiga delays disease progression and improves survival of men with metastatic castration-resistant prostate cancer. The LATITUTDE trial showed that adding Zytiga to GnRH agonists slows progression and improves survival of men with high-risk metastatic castration-sensitive prostate cancer.

Dosage

Dosing Info: Zytiga is pill taken with prednisone once daily on an empty stomach.

Side Effects

Common side effects include fatigue, joint pain, nausea, diarrhea, headache, hot flashes, swelling and high blood pressure. Potential serious side effects include elevated potassium, hormone imbalances and liver toxicity.

For More Info: https://www.zytiga.com/

Co-Pay Program Info: http://www.janssenprescriptionassistance.com/zytiga-cost-assistance

Patient Assistance Program Info: http://www.janssenprescriptionassistance.com/zytiga-cost-assistance

Last Reviewed: September 19, 2018

© 2026 Smart + Strong All Rights Reserved.